

## **osteolabs to present new clinical data for OsteoTest at the upcoming WCO-IOF-ESCEO Congress**

**New data provide further evidence for CIM (Calcium isotope marker) technology as new sensitive diagnostic method for early risk assessment and therapeutic monitoring for osteoporosis and Chronic Kidney Disease (CKD)-associated bone disease**

**Kiel (Germany), April 2nd, 2025** – osteolabs GmbH, an innovative diagnostic company applying its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide, announced today that three abstracts will be presented at the world’s leading clinical conference on bone, joint and muscle health (WCO-IOF-ESCEO) taking place in Rome from April 10-13, 2025.

Firstly, results from a feasibility study will highlight the utility of OsteoTest for monitoring Denosumab treatment in osteoporotic patients and enable personalized treatment options. Secondly, a first correlation-based approach predicting DXA values using CIM data from OsteoTest results from close to 300 patient data will be showcased as well.

Lastly, the abstract entitled “CALCIUM ISOTOPE RATIOS IN SERUM INFORM ON SKELETAL CALCIUM BALANCE IN PATIENTS ON DIALYSIS” will be presented by **Professor Anton Eisenhauer** who is a **key inventor of the CIM technology and osteolabs’ Chief Scientific Officer**. The related presentation will feature key results from a clinical study demonstrating that CIM\_Serum is a significant and independent predictor of Bone Calcium Balance (BCaB) in dialysis patients providing a comprehensive, real-time assessment of bone health for patients with CKD-associated bone disease.

“We are very happy to present these recent important findings further supporting the clinical body of evidence for OsteoTest to enable early osteoporosis risk assessment and therapeutic control,” said **Prof. Anton Eisenhauer**. “In addition, we are excited about the possibility to expand our CIM technology to CKD-associated bone disease representing a significant medical burden for dialysis patients.”

### **Details of the upcoming event:**

#### **25<sup>th</sup> Edition of the WCO-IOF-ESCEO Congress (Rome)**

- 1) **Oral presentation title:** OP13 - P147 CALCIUM ISOTOPE RATIOS IN SERUM INFORM ON SKELETAL CALCIUM BALANCE IN PATIENTS ON DIALYSIS

**Date and Time:** April 12, 2025; 2-3 p.m.

**Presenter:** Prof. Anton Eisenhauer

- 2) **Poster presentation:** P146 UTILIZING CALCIUM ISOTOPE MARKER (CIM) TECHNOLOGY FOR MONITORING DENOSUMAB TREATMENT IN OSTEOPOROSIS
- 3) **Poster presentation:** P148 A CORRELATION-BASED APPROACH TO PREDICTING DXA USING THE CALCIUM ISOTOPE MARKER (CIM)

**For further information please contact:**

osteolabs GmbH  
Kathrin Hagen (PR)  
+49 431 990730  
[kh@osteolabs.de](mailto:kh@osteolabs.de)

**About osteolabs GmbH – [www.osteolabs.de](http://www.osteolabs.de)**

osteolabs GmbH is an innovative diagnostics company which was spun out from GEOMAR Helmholtz Centre for Ocean Research Kiel and the Helmholtz Association Berlin in 2018. The company deploys its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide with an initial focus on early risk determination of osteoporosis.